Belimumabe comparado à terapia padrão do Sistema Único de Saúde no tratamento da nefrite lúpica nos estágios III, IV e V: revisão rápida

Fernandes Nascimento, Maria Helha; Barbosa, Aurélio de Melo; Ferreira, Fernanda Pimenta Simon; Camargo, Erika Barbosa.
Rev. Cient. Esc. Estadual Saúde Pública de Goiás Cândido Santiago ; 9 (Ed. Especial, 1ª Oficina de Elaboração de Pareceres Técnicos Científicos (PTC): 9e8, 2023. ilus, tab
Artigo em Português | LILACS, CONASS, Coleciona SUS, SES-GO | ID: biblio-1524065

Documentos relacionados

  1. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results.
  2. The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis.
  3. Development of a novel, highly sensitive assay for quantification of minimal residual B cells in autoimmune disease and comparison to traditional methods across B-cell-depleting agents.
  4. Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: a systematic review and meta-analysis of 4,068 patients.
  5. Systematic review and meta-analysis for 2023 clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis.
  6. Rituximab in the Management of Autoimmune Bullous Diseases: A Treatment-Resistant Case Series from a Single Central European Referral Center.
  7. The use of rituximab as an adjuvant in the treatment of oral pemphigus vulgaris.
  8. Immunosuppressive and glucocorticoid therapy for the treatment of ANCA-asssociated vasculitis.
  9. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis.
  10. Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients.